

Ie-Ming Shih

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2914247/publications.pdf>

Version: 2024-02-01

280
papers

34,512
citations

3149

92
h-index

3903

177
g-index

284
all docs

284
docs citations

284
times ranked

29996
citing authors

#	ARTICLE	IF	CITATIONS
1	Current and Emerging Methods for Ovarian Cancer Screening and Diagnostics: A Comprehensive Review. <i>Cancers</i> , 2022, 14, 2885.	1.7	22
2	The Origin of Ovarian Cancer Species and Precancerous Landscape. <i>American Journal of Pathology</i> , 2021, 191, 26-39.	1.9	102
3	Genome-wide mutation analysis in precancerous lesions of endometrial carcinoma. <i>Journal of Pathology</i> , 2021, 253, 119-128.	2.1	27
4	Sub-millimeter endoscope demonstrates feasibility of in vivo reflectance imaging, fluorescence imaging, and cell collection in the fallopian tubes. <i>Journal of Biomedical Optics</i> , 2021, 26, .	1.4	9
5	Uterine serous carcinoma: key advances and novel treatment approaches. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1165-1174.	1.2	40
6	A novel human endometrial epithelial cell line for modeling gynecological diseases and for drug screening. <i>Laboratory Investigation</i> , 2021, 101, 1505-1512.	1.7	9
7	Mutation and methylation profiles of ectopic and eutopic endometrial tissues. <i>Journal of Pathology</i> , 2021, 255, 387-398.	2.1	8
8	Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 163, 246-253.	0.6	62
9	Progestin and aromatase inhibitor therapy in recurrent, estrogen/progestin receptor positive uterine carcinosarcoma: A case report. <i>Gynecologic Oncology Reports</i> , 2021, 38, 100877.	0.3	2
10	Development of small molecule inhibitors targeting PBX1 transcription signaling as a novel cancer therapeutic strategy. <i>IScience</i> , 2021, 24, 103297.	1.9	12
11	The Origin and Pathogenesis of Endometriosis. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2020, 15, 71-95.	9.6	213
12	Oncogenic <i>BRAF</i> and <i>KRAS</i> mutations in endosalpingiosis. <i>Journal of Pathology</i> , 2020, 250, 148-158.	2.1	18
13	Molecular Classification and Emerging Targeted Therapy in Endometrial Cancer. <i>International Journal of Gynecological Pathology</i> , 2020, 39, 26-35.	0.9	69
14	Pathology and Pathogenesis of Adenomyosis. <i>Seminars in Reproductive Medicine</i> , 2020, 38, 108-118.	0.5	25
15	Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers. <i>Cancer Research</i> , 2020, 80, 4514-4526.	0.4	44
16	Urothelial Carcinomas With Trophoblastic Differentiation, Including Choriocarcinoma. <i>American Journal of Surgical Pathology</i> , 2020, 44, 1322-1330.	2.1	15
17	Methylomic Landscapes of Ovarian Cancer Precursor Lesions. <i>Clinical Cancer Research</i> , 2020, 26, 6310-6320.	3.2	15
18	Epigenomic Reprogramming toward Mesenchymal-Epithelial Transition in Ovarian-Cancer-Associated Mesenchymal Stem Cells Drives Metastasis. <i>Cell Reports</i> , 2020, 33, 108473.	2.9	34

#	ARTICLE	IF	CITATIONS
19	Inactivation of Arid1a in the endometrium is associated with endometrioid tumorigenesis through transcriptional reprogramming. <i>Nature Communications</i> , 2020, 11, 2717.	5.8	45
20	Assessing aneuploidy with repetitive element sequencing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 4858-4863.	3.3	50
21	Epithelial Cells in Endometriosis and Adenomyosis Upregulate STING Expression. <i>Reproductive Sciences</i> , 2020, 27, 1276-1284.	1.1	14
22	Not All Peritoneal Implants Are Created Equal. <i>Gynecologic Oncology</i> , 2020, 156, 1-2.	0.6	2
23	Low-grade serous ovarian cancer: State of the science. <i>Gynecologic Oncology</i> , 2020, 156, 715-725.	0.6	74
24	Gestational Trophoblastic Lesions. , 2020, , 871-903.		0
25	NAC1 attenuates BCL6 negative autoregulation and functions as a BCL6 coactivator of FOXQ1 transcription in cancer cells. <i>Aging</i> , 2020, 12, 9275-9291.	1.4	6
26	Epithelial Tumors of the Ovary. , 2019, , 841-966.		10
27	Gestational Trophoblastic Tumors and Related Tumorlike Lesions. , 2019, , 1307-1375.		2
28	Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer. <i>EBioMedicine</i> , 2019, 47, 184-194.	2.7	9
29	PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8+ T-cell Function. <i>Cancer Immunology Research</i> , 2019, 7, 257-268.	1.6	108
30	Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor Therapy. <i>Clinical Cancer Research</i> , 2019, 25, 5584-5594.	3.2	80
31	Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. <i>Cancer</i> , 2019, 125, 1963-1972.	2.0	39
32	Cytomorphologic and molecular analyses of fallopian tube fimbrial brushings for diagnosis of serous tubal intraepithelial carcinoma. <i>Cancer Cytopathology</i> , 2019, 127, 192-201.	1.4	1
33	TET1 reprograms the epithelial ovarian cancer epigenome and reveals casein kinase 2 β as a therapeutic target. <i>Journal of Pathology</i> , 2019, 248, 363-376.	2.1	23
34	Follicular fluid has more to offer: Insulin-like growth factor axis on ovarian carcinogenesis. <i>EBioMedicine</i> , 2019, 41, 30-31.	2.7	1
35	Genomic characterization of genes encoding histone acetylation modulator proteins identifies therapeutic targets for cancer treatment. <i>Nature Communications</i> , 2019, 10, 733.	5.8	39
36	Analysis of Telomere Lengths in p53 Signatures and Incidental Serous Tubal Intraepithelial Carcinomas Without Concurrent Ovarian Cancer. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1083-1091.	2.1	15

#	ARTICLE	IF	CITATIONS
37	Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1462-1472.	2.1	33
38	Long Interspersed Nuclear Element 1 Retrotransposons Become Deregulated during the Development of Ovarian Cancer Precursor Lesions. <i>American Journal of Pathology</i> , 2019, 189, 513-520.	1.9	35
39	Genomic landscape and evolutionary trajectories of ovarian cancer precursor lesions. <i>Journal of Pathology</i> , 2019, 248, 41-50.	2.1	84
40	T cell-inflamed phenotype and increased Foxp3 expression in infiltrating T-cells of mismatch-repair deficient endometrial cancers. <i>Modern Pathology</i> , 2019, 32, 576-584.	2.9	29
41	Proteome-wide Tyrosine Phosphorylation Analysis Reveals Dysregulated Signaling Pathways in Ovarian Tumors. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 448-460.	2.5	19
42	BRAFV600E-mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma. <i>Oncotarget</i> , 2019, 10, 6870-6878.	0.8	10
43	Inhibition of ovarian tumor cell invasiveness by targeting SYK in the tyrosine kinase signaling pathway. <i>Oncogene</i> , 2018, 37, 3778-3789.	2.6	22
44	Precancerous Lesions of Ovarian Cancer—A US Perspective. <i>Journal of the National Cancer Institute</i> , 2018, 110, 692-693.	3.0	9
45	Independent development of endometrial epithelium and stroma within the same endometriosis. <i>Journal of Pathology</i> , 2018, 245, 265-269.	2.1	53
46	Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer. <i>Cell Reports</i> , 2018, 22, 3393-3400.	2.9	77
47	Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	178
48	Epithelial Tumors of the Ovary. , 2018, , 1-128.		0
49	Gestational Trophoblastic Tumors and Related Tumorlike Lesions. , 2018, , 1-71.		1
50	Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A Multicenter Study. <i>Cancer Prevention Research</i> , 2018, 11, 697-706.	0.7	47
51	Reply to Haffner et al.: DNA hypomethylation renders tumors more immunogenic. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E8583-E8584.	3.3	5
52	Loss of ARID1A expression in endometrial samplings is associated with the risk of endometrial carcinoma. <i>Gynecologic Oncology</i> , 2018, 150, 426-431.	0.6	36
53	Methylomic Analysis of Ovarian Cancers Identifies Tumor-Specific Alterations Readily Detectable in Early Precursor Lesions. <i>Clinical Cancer Research</i> , 2018, 24, 6536-6547.	3.2	39
54	Epithelial Tumors of the Ovary. , 2018, , 1-128.		0

#	ARTICLE	IF	CITATIONS
55	Human transposon insertion profiling: Analysis, visualization and identification of somatic LINE-1 insertions in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E733-E740.	3.3	86
56	Tubal origin of ovarian cancer—The double-edged sword of haemoglobin. Journal of Pathology, 2017, 242, 3-6.	2.1	18
57	Cancer-Associated Mutations in Endometriosis without Cancer. New England Journal of Medicine, 2017, 376, 1835-1848.	13.9	451
58	Cancer Implications for Patients with Endometriosis. Seminars in Reproductive Medicine, 2017, 35, 110-116.	0.5	76
59	Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma. Nature Communications, 2017, 8, 990.	5.8	169
60	High grade serous ovarian carcinomas originate in the fallopian tube. Nature Communications, 2017, 8, 1093.	5.8	515
61	Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma. Human Pathology, 2017, 68, 87-91.	1.1	19
62	PD-L1 Expression in Human Placentas and Gestational Trophoblastic Diseases. International Journal of Gynecological Pathology, 2017, 36, 146-153.	0.9	145
63	Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?. Gynecologic Oncology, 2017, 147, 85-91.	0.6	74
64	Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E10981-E10990.	3.3	217
65	CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis. Modern Pathology, 2017, 30, 297-303.	2.9	48
66	CINdex: A Bioconductor Package for Analysis of Chromosome Instability in DNA Copy Number Data. Cancer Informatics, 2017, 16, 117693511774663.	0.9	10
67	Elucidating the pathogenesis of synchronous and metachronous tumors in a woman with endometrioid carcinomas using a whole-exome sequencing approach. Journal of Physical Education and Sports Management, 2017, 3, a001693.	0.5	12
68	Endometriosis: benign, malignant, or something in between?. Oncotarget, 2017, 8, 78263-78264.	0.8	27
69	The novel ZIP4 regulation and its role in ovarian cancer. Oncotarget, 2017, 8, 90090-90107.	0.8	27
70	Diagnostic potential of tumor DNA from ovarian cyst fluid. ELife, 2016, 5, .	2.8	30
71	Expression of Cell Competition Markers at the Interface between p53 Signature and Normal Epithelium in the Human Fallopian Tube. PLoS ONE, 2016, 11, e0156069.	1.1	1
72	Ovarian Cancer Chemoresistance Relies on the Stem Cell Reprogramming Factor PBX1. Cancer Research, 2016, 76, 6351-6361.	0.4	61

#	ARTICLE	IF	CITATIONS
73	CCNE1 amplification and centrosome number abnormality in serous tubal intraepithelial carcinoma: further evidence supporting its role as a precursor of ovarian high-grade serous carcinoma. <i>Modern Pathology</i> , 2016, 29, 1254-1261.	2.9	72
74	Biologically inspired survival analysis based on integrating gene expression as mediator with genomic variants. <i>Computers in Biology and Medicine</i> , 2016, 77, 231-239.	3.9	1
75	Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence. <i>Cancer Prevention Research</i> , 2016, 9, 713-720.	0.7	7
76	Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2016, 35, 48-55.	0.9	136
77	Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer. <i>Cell</i> , 2016, 166, 755-765.	13.5	804
78	Inactivating ARID1A Tumor Suppressor Enhances TERT Transcription and Maintains Telomere Length in Cancer Cells. <i>Journal of Biological Chemistry</i> , 2016, 291, 9690-9699.	1.6	45
79	The Dualistic Model of Ovarian Carcinogenesis. <i>American Journal of Pathology</i> , 2016, 186, 733-747.	1.9	717
80	ChIP-BIT: Bayesian inference of target genes using a novel joint probabilistic model of ChIP-seq profiles. <i>Nucleic Acids Research</i> , 2016, 44, e65-e65.	6.5	15
81	BACOM2.0 facilitates absolute normalization and quantification of somatic copy number alterations in heterogeneous tumor. <i>Scientific Reports</i> , 2015, 5, 13955.	1.6	6
82	Clonality analysis of combined Brenner and mucinous tumours of the ovary reveals their monoclonal origin. <i>Journal of Pathology</i> , 2015, 237, 146-151.	2.1	48
83	Adenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms. <i>Gynecologic Oncology Research and Practice</i> , 2015, 2, 1.	3.6	27
84	Increased proliferation in atypical hyperplasia/endometrioid intraepithelial neoplasia of the endometrium with concurrent inactivation of ARID1A and PTEN tumour suppressors. <i>Journal of Pathology: Clinical Research</i> , 2015, 1, 186-193.	1.3	38
85	Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. <i>Nature Medicine</i> , 2015, 21, 231-238.	15.2	530
86	Precursors of ovarian cancer in the fallopian tube: serous tubal intraepithelial carcinoma – an update. <i>Journal of Obstetrics and Gynaecology Research</i> , 2015, 41, 6-11.	0.6	34
87	Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules. <i>Cancer Cell</i> , 2015, 28, 82-96.	7.7	125
88	Mevalonate Pathway Antagonist Suppresses Formation of Serous Tubal Intraepithelial Carcinoma and Ovarian Carcinoma in Mouse Models. <i>Clinical Cancer Research</i> , 2015, 21, 4652-4662.	3.2	48
89	ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors. <i>Cancer Discovery</i> , 2015, 5, 752-767.	7.7	361
90	Immunohistochemical expression of ARID1A in penile squamous cell carcinomas: a tissue microarray study of 112 cases. <i>Human Pathology</i> , 2015, 46, 761-766.	1.1	10

#	ARTICLE	IF	CITATIONS
91	GATA-3 Expression in Trophoblastic Tissues. <i>American Journal of Surgical Pathology</i> , 2015, 39, 101-108.	2.1	80
92	Laminin C1 expression by uterine carcinoma cells is associated with tumor progression. <i>Gynecologic Oncology</i> , 2015, 139, 338-344.	0.6	37
93	Loss of ALDH1A1 expression is an early event in the pathogenesis of ovarian high-grade serous carcinoma. <i>Modern Pathology</i> , 2015, 28, 437-445.	2.9	16
94	UNDO: a Bioconductor R package for unsupervised deconvolution of mixed gene expressions in tumor samples. <i>Bioinformatics</i> , 2015, 31, 137-139.	1.8	60
95	KDDN: an open-source Cytoscape app for constructing differential dependency networks with significant rewiring. <i>Bioinformatics</i> , 2015, 31, 287-289.	1.8	17
96	Molecular analysis of ovarian mucinous carcinoma reveals different cell of origins. <i>Oncotarget</i> , 2015, 6, 22949-22958.	0.8	17
97	Expression Patterns of VEGF and Flk-1 in Human Endometrium during the Menstrual Cycle. <i>Journal of Reproduction and Infertility</i> , 2015, 16, 3-9.	1.0	35
98	The emerging roles of ARID1A in tumor suppression. <i>Cancer Biology and Therapy</i> , 2014, 15, 655-664.	1.5	200
99	ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas. <i>Modern Pathology</i> , 2014, 27, 255-261.	2.9	110
100	Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma. <i>Modern Pathology</i> , 2014, 27, 1014-1019.	2.9	54
101	Notch3 Interactome Analysis Identified WWP2 as a Negative Regulator of Notch3 Signaling in Ovarian Cancer. <i>PLoS Genetics</i> , 2014, 10, e1004751.	1.5	64
102	Mutational analysis of <i>BRAF</i> and <i>KRAS</i> in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants. <i>Journal of Pathology</i> , 2014, 232, 16-22.	2.1	52
103	BRAF Mutation Is Associated With a Specific Cell Type With Features Suggestive of Senescence in Ovarian Serous Borderline (Atypical Proliferative) Tumors. <i>American Journal of Surgical Pathology</i> , 2014, 38, 1603-1611.	2.1	50
104	Roles of Deletion of Arid1a, a Tumor Suppressor, in Mouse Ovarian Tumorigenesis. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	105
105	Characterization of the Immune Cell Repertoire in the Normal Fallopian Tube. <i>International Journal of Gynecological Pathology</i> , 2014, 33, 581-591.	0.9	46
106	Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy. <i>Journal of Pathology</i> , 2014, 232, 473-481.	2.1	81
107	Long Interspersed Element-1 Protein Expression Is a Hallmark of Many Human Cancers. <i>American Journal of Pathology</i> , 2014, 184, 1280-1286.	1.9	250
108	A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development. <i>Journal of Pathology</i> , 2014, 233, 228-237.	2.1	112

#	ARTICLE	IF	CITATIONS
109	The pathogenesis of atypical proliferative Brenner tumor: an immunohistochemical and molecular genetic analysis. <i>Modern Pathology</i> , 2014, 27, 231-237.	2.9	41
110	Origin and Pathogenesis of Pelvic (Ovarian, Tubal, and Primary Peritoneal) Serous Carcinoma. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2014, 9, 27-45.	9.6	142
111	ARID1A immunohistochemistry improves outcome prediction in invasive urothelial carcinoma of urinary bladder. <i>Human Pathology</i> , 2014, 45, 2233-2239.	1.1	24
112	RSF1 Is a Positive Regulator of NF- κ B-Induced Gene Expression Required for Ovarian Cancer Chemoresistance. <i>Cancer Research</i> , 2014, 74, 2258-2269.	0.4	33
113	Identification of the NAC1-Regulated Genes in Ovarian Cancer. <i>American Journal of Pathology</i> , 2014, 184, 133-140.	1.9	21
114	Gene expression signatures of primary and metastatic uterine leiomyosarcoma. <i>Human Pathology</i> , 2014, 45, 691-700.	1.1	63
115	Screening for Ovarian Cancer: A Reality Check. <i>Current Obstetrics and Gynecology Reports</i> , 2013, 2, 73-75.	0.3	1
116	Bokhman's dualistic model of endometrial carcinoma. Revisited. <i>Gynecologic Oncology</i> , 2013, 129, 271-272.	0.6	18
117	<i>TERT</i> promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 6021-6026.	3.3	1,202
118	Evaluation of DNA from the Papanicolaou Test to Detect Ovarian and Endometrial Cancers. <i>Science Translational Medicine</i> , 2013, 5, 167ra4.	5.8	264
119	Dedifferentiated endometrioid adenocarcinoma: An under-recognized but aggressive tumor?. <i>Gynecologic Oncology Case Reports</i> , 2013, 5, 25-27.	0.9	14
120	Ovarian Brenner tumour: A morphologic and immunohistochemical analysis suggesting an origin from fallopian tube epithelium. <i>European Journal of Cancer</i> , 2013, 49, 3839-3849.	1.3	68
121	Fallopian tube precursors of ovarian low- and high-grade serous neoplasms. <i>Histopathology</i> , 2013, 62, 44-58.	1.6	238
122	High level of chromosomal aberration in ovarian cancer genome correlates with poor clinical outcome. <i>Gynecologic Oncology</i> , 2013, 128, 500-505.	0.6	20
123	Loss of ARID1A Expression Correlates With Stages of Tumor Progression in Uterine Endometrioid Carcinoma. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1342-1348.	2.1	88
124	Pathogenesis and the Role of ARID1A Mutation in Endometriosis-related Ovarian Neoplasms. <i>Advances in Anatomic Pathology</i> , 2013, 20, 45-52.	2.4	98
125	Rsf1, a chromatin remodelling protein, interacts with cyclin E1 and promotes tumour development. <i>Journal of Pathology</i> , 2013, 229, 559-568.	2.1	32
126	Genomic and network analysis to study the origin of ovarian cancer. <i>Systems Biomedicine (Austin, Tex)</i> 0,78 BT / Overlock 10	0.78	10

#	ARTICLE	IF	CITATIONS
127	The roles of ARID1A in gynecologic cancer. <i>Journal of Gynecologic Oncology</i> , 2013, 24, 376.	1.0	53
128	Molecular Pathology of Ovarian Cancer. , 2013, , 129-149.		1
129	Loss of NAC1 Expression Is Associated with Defective Bony Patterning in the Murine Vertebral Axis. <i>PLoS ONE</i> , 2013, 8, e69099.	1.1	19
130	The Role of Forkhead Box Q1 Transcription Factor in Ovarian Epithelial Carcinomas. <i>International Journal of Molecular Sciences</i> , 2012, 13, 13881-13893.	1.8	29
131	Endocervical-type Mucinous Borderline Tumors are Related to Endometrioid Tumors Based on Mutation and Loss of Expression of ARID1A. <i>International Journal of Gynecological Pathology</i> , 2012, 31, 297-303.	0.9	74
132	Ki-67 Labeling Index as an Adjunct in the Diagnosis of Serous Tubal Intraepithelial Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2012, 31, 416-422.	0.9	50
133	Validation of an Algorithm for the Diagnosis of Serous Tubal Intraepithelial Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2012, 31, 243-253.	0.9	125
134	Detecting aberrant signal transduction pathways from high-throughput data using GIST algorithm. , 2012, , .		2
135	Defining NOTCH3 Target Genes in Ovarian Cancer. <i>Cancer Research</i> , 2012, 72, 2294-2303.	0.4	57
136	NAC1 Is an Actin-Binding Protein That Is Essential for Effective Cytokinesis in Cancer Cells. <i>Cancer Research</i> , 2012, 72, 4085-4096.	0.4	29
137	Loss of ARID1A Expression Is an Early Molecular Event in Tumor Progression From Ovarian Endometriotic Cyst to Clear Cell and Endometrioid Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 1310-1315.	1.2	148
138	The Diagnostic and Biological Implications of Laminin Expression in Serous Tubal Intraepithelial Carcinoma. <i>American Journal of Surgical Pathology</i> , 2012, 36, 1826-1834.	2.1	48
139	Identification of Molecular Pathway Aberrations in Uterine Serous Carcinoma by Genome-wide Analyses. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1503-1513.	3.0	231
140	Accurate identification of significant aberrations in contaminated cancer genome. , 2012, , .		0
141	Dysfunction of Nucleus Accumbens-1 Activates Cellular Senescence and Inhibits Tumor Cell Proliferation and Oncogenesis. <i>Cancer Research</i> , 2012, 72, 4262-4275.	0.4	27
142	Mutant BRAF Induces DNA Strand Breaks, Activates DNA Damage Response Pathway, and Up-Regulates Glucose Transporter-1 in Nontransformed Epithelial Cells. <i>American Journal of Pathology</i> , 2012, 180, 1179-1188.	1.9	29
143	Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma. <i>Human Pathology</i> , 2012, 43, 2197-2206.	1.1	59
144	Functional Analysis of In-frame Indel ARID1A Mutations Reveals New Regulatory Mechanisms of Its Tumor Suppressor Functions. <i>Neoplasia</i> , 2012, 14, 986-993.	2.3	89

#	ARTICLE	IF	CITATIONS
145	Pathogenesis and New Therapeutic Targets of Ovarian Cancer. <i>Journal of Oncology</i> , 2012, 2012, 1-2.	0.6	1
146	DNA Damage Response is Prominent in Ovarian High-Grade Serous Carcinomas, Especially Those with Rsf-1 (HBXAP) Overexpression. <i>Journal of Oncology</i> , 2012, 2012, 1-7.	0.6	16
147	<i>TP53</i> mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma—evidence supporting the clonal relationship of the two lesions. <i>Journal of Pathology</i> , 2012, 226, 421-426.	2.1	332
148	Low-grade serous carcinomas of the ovary contain very few point mutations. <i>Journal of Pathology</i> , 2012, 226, 413-420.	2.1	186
149	A Fluorescence Light-Up Ag Nanocluster Probe That Discriminates Single-Nucleotide Variants by Emission Color. <i>Journal of the American Chemical Society</i> , 2012, 134, 11550-11558.	6.6	238
150	Prognostic and therapeutic impact of the chromosome 20q13.2 <i>ZNF217</i> locus amplification in ovarian clear cell carcinoma. <i>Cancer</i> , 2012, 118, 2846-2857.	2.0	51
151	Ovarian Cancer is an Imported Disease: Fact or Fiction?. <i>Current Obstetrics and Gynecology Reports</i> , 2012, 1, 1-9.	0.3	105
152	Identification of PBX1 Target Genes in Cancer Cells by Global Mapping of PBX1 Binding Sites. <i>PLoS ONE</i> , 2012, 7, e36054.	1.1	40
153	Cell cycle-dependent alteration in NAC1 nuclear body dynamics and morphology. <i>Physical Biology</i> , 2011, 8, 015005.	0.8	23
154	Somatic Mutations of PPP2R1A in Ovarian and Uterine Carcinomas. <i>American Journal of Pathology</i> , 2011, 178, 1442-1447.	1.9	88
155	Overexpression of a Chromatin Remodeling Factor, RSF-1/HBXAP, Correlates with Aggressive Oral Squamous Cell Carcinoma. <i>American Journal of Pathology</i> , 2011, 178, 2407-2415.	1.9	44
156	Prevalence of the Alternative Lengthening of Telomeres Telomere Maintenance Mechanism in Human Cancer Subtypes. <i>American Journal of Pathology</i> , 2011, 179, 1608-1615.	1.9	423
157	Osteopontin expression in ovarian carcinoma effusions is related to improved clinical outcome. <i>Human Pathology</i> , 2011, 42, 991-997.	1.1	11
158	Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—Shifting the paradigm. <i>Human Pathology</i> , 2011, 42, 918-931.	1.1	932
159	<i>ARID1A</i> , a Factor That Promotes Formation of SWI/SNF-Mediated Chromatin Remodeling, Is a Tumor Suppressor in Gynecologic Cancers. <i>Cancer Research</i> , 2011, 71, 6718-6727.	0.4	390
160	Mutation and Loss of Expression of ARID1A in Uterine Low-grade Endometrioid Carcinoma. <i>American Journal of Surgical Pathology</i> , 2011, 35, 625-632.	2.1	251
161	Rsf-1 (HBXAP) Expression is Associated With Advanced Stage and Lymph Node Metastasis in Ovarian Clear Cell Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2011, 30, 30-35.	0.9	21
162	Evolution of a Trophoblastic Tumor From an Endometrioid Carcinoma—A Morphological and Molecular Analysis. <i>International Journal of Gynecological Pathology</i> , 2011, 30, 117-120.	0.9	15

#	ARTICLE	IF	CITATIONS
163	Papillary Tubal Hyperplasia. American Journal of Surgical Pathology, 2011, 35, 1605-1614.	2.1	140
164	Diagnosis of Serous Tubal Intraepithelial Carcinoma Based on Morphologic and Immunohistochemical Features. American Journal of Surgical Pathology, 2011, 35, 1766-1775.	2.1	151
165	Mutation of <i>PPP2R1A</i> : a new clue in unveiling the pathogenesis of uterine serous carcinoma. Journal of Pathology, 2011, 224, 1-4.	2.1	13
166	Amplification of the ch19p13.2 NACC1 locus in ovarian high-grade serous carcinoma. Modern Pathology, 2011, 24, 638-645.	2.9	52
167	Trophoblastic vasculogenic mimicry in gestational choriocarcinoma. Modern Pathology, 2011, 24, 646-652.	2.9	22
168	Telomere length in different histologic types of ovarian carcinoma with emphasis on clear cell carcinoma. Modern Pathology, 2011, 24, 1139-1145.	2.9	29
169	Gestational Trophoblastic Tumors and Related Tumor-Like Lesions. , 2011, , 1075-1135.		13
170	Are All Pelvic (Nonuterine) Serous Carcinomas of Tubal Origin?. American Journal of Surgical Pathology, 2010, 34, 1407-1416.	2.1	395
171	Shortened Telomeres in Serous Tubal Intraepithelial Carcinoma: An Early Event in Ovarian High-grade Serous Carcinogenesis. American Journal of Surgical Pathology, 2010, 34, 829-836.	2.1	127
172	Distinct DNA methylation profiles in ovarian serous neoplasms and their implications in ovarian carcinogenesis. American Journal of Obstetrics and Gynecology, 2010, 203, 584.e1-584.e22.	0.7	43
173	Precursor Lesions of High-Grade Serous Ovarian Carcinoma: Morphological and Molecular Characteristics. Journal of Oncology, 2010, 2010, 1-9.	0.6	64
174	Expression of Fatty Acid Synthase Depends on NAC1 and Is Associated with Recurrent Ovarian Serous Carcinomas. Journal of Oncology, 2010, 2010, 1-12.	0.6	57
175	Lack of a Y-Chromosomal Complement in the Majority of Gestational Trophoblastic Neoplasms. Journal of Oncology, 2010, 2010, 1-6.	0.6	13
176	DNA Copy Numbers Profiles in Affinity-Purified Ovarian Clear Cell Carcinoma. Clinical Cancer Research, 2010, 16, 1997-2008.	3.2	85
177	Rsf-1, a Chromatin Remodeling Protein, Induces DNA Damage and Promotes Genomic Instability. Journal of Biological Chemistry, 2010, 285, 38260-38269.	1.6	57
178	The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory. American Journal of Surgical Pathology, 2010, 34, 433-443.	2.1	1,503
179	Clinicopathological Significance of Loss of ARID1A Immunoreactivity in Ovarian Clear Cell Carcinoma. International Journal of Molecular Sciences, 2010, 11, 5120-5128.	1.8	100
180	Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase. Modern Pathology, 2010, 23, 844-855.	2.9	84

#	ARTICLE	IF	CITATIONS
181	Dendritic cells transduced with Rsf-1/HBXAP gene generate specific cytotoxic T lymphocytes against ovarian cancer in vitro. <i>Biochemical and Biophysical Research Communications</i> , 2010, 394, 633-638.	1.0	7
182	Frequent Mutations of Chromatin Remodeling Gene <i>ARID1A</i> in Ovarian Clear Cell Carcinoma. <i>Science</i> , 2010, 330, 228-231.	6.0	1,090
183	<i>ARID1A</i> Mutations in Endometriosis-Associated Ovarian Carcinomas. <i>New England Journal of Medicine</i> , 2010, 363, 1532-1543.	13.9	1,460
184	Notch3 Overexpression Is Related to the Recurrence of Ovarian Cancer and Confers Resistance to Carboplatin. <i>American Journal of Pathology</i> , 2010, 177, 1087-1094.	1.9	162
185	HLA-G and Immune Evasion in Cancer Cells. <i>Journal of the Formosan Medical Association</i> , 2010, 109, 248-257.	0.8	64
186	Oncoproteomic Analysis Reveals Co-Upregulation of RELA and STAT5 in Carboplatin Resistant Ovarian Carcinoma. <i>PLoS ONE</i> , 2010, 5, e11198.	1.1	79
187	Jagged1 Expression Regulated by Notch3 and Wnt/ β -catenin Signaling Pathways in Ovarian Cancer. <i>Oncotarget</i> , 2010, 1, 210-218.	0.8	86
188	Gestational Trophoblastic Lesions. , 2009, , 645-665.		4
189	Analyzing DNA Copy Number Changes Using Fused Margin Regression. , 2009, , .		0
190	Analysis of DNA Copy Number Alterations in Ovarian Serous Tumors Identifies New Molecular Genetic Changes in Low-Grade and High-Grade Carcinomas. <i>Cancer Research</i> , 2009, 69, 4036-4042.	0.4	166
191	Accurate Estimation of Genomic Deletions and Normal Cell Contamination by Bayesian Analysis of Mixtures. , 2009, , .		0
192	Functional Analysis of 11q13.5 Amplicon Identifies <i>Rsf-1</i> (<i>HBXAP</i>) as a Gene Involved in Paclitaxel Resistance in Ovarian Cancer. <i>Cancer Research</i> , 2009, 69, 1407-1415.	0.4	70
193	Ovarian Low-grade and High-grade Serous Carcinoma. <i>Advances in Anatomic Pathology</i> , 2009, 16, 267-282.	2.4	477
194	Pathogenesis of ovarian cancer: clues from selected overexpressed genes. <i>Future Oncology</i> , 2009, 5, 1641-1657.	1.1	49
195	Functional Genomic Analysis Identified Epidermal Growth Factor Receptor Activation as the Most Common Genetic Event in Oral Squamous Cell Carcinoma. <i>Cancer Research</i> , 2009, 69, 2568-2576.	0.4	143
196	IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. <i>Modern Pathology</i> , 2009, 22, 469-475.	2.9	125
197	Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions. <i>Human Pathology</i> , 2009, 40, 1453-1460.	1.1	66
198	Ovarian Cancer. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2009, 4, 287-313.	9.6	576

#	ARTICLE	IF	CITATIONS
199	Advances in the diagnosis of gestational trophoblastic tumors and tumor-like lesions. <i>Expert Opinion on Medical Diagnostics</i> , 2009, 3, 371-380.	1.6	5
200	Frequent Activating Mutations of PIK3CA in Ovarian Clear Cell Carcinoma. <i>American Journal of Pathology</i> , 2009, 174, 1597-1601.	1.9	409
201	Defining the Cut Point Between Low-grade and High-grade Ovarian Serous Carcinomas. <i>American Journal of Surgical Pathology</i> , 2009, 33, 1220-1224.	2.1	75
202	Cystic and Adenofibromatous Clear Cell Carcinomas of the Ovary. <i>American Journal of Surgical Pathology</i> , 2009, 33, 844-853.	2.1	126
203	Utility of p16 Expression for Distinction of Uterine Serous Carcinomas From Endometrial Endometrioid and Endocervical Adenocarcinomas. <i>American Journal of Surgical Pathology</i> , 2009, 33, 1504-1514.	2.1	163
204	Metastatic Epithelioid Trophoblastic Tumor in a Male Patient With Mixed Germ-cell Tumor of the Testis. <i>American Journal of Surgical Pathology</i> , 2009, 33, 1902-1905.	2.1	20
205	Amplification of 11q13 in ovarian carcinoma. <i>Genes Chromosomes and Cancer</i> , 2008, 47, 481-489.	1.5	116
206	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers. <i>Clinical Chemistry</i> , 2008, 54, e11-e79.	1.5	539
207	Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. <i>American Journal of Obstetrics and Gynecology</i> , 2008, 198, 351-356.	0.7	178
208	Expression of the chromatin remodeling factor Rsf-1 is down-regulated in breast carcinoma effusions. <i>Human Pathology</i> , 2008, 39, 616-622.	1.1	10
209	Power of the Eternal Youth. <i>American Journal of Pathology</i> , 2008, 173, 911-914.	1.9	12
210	Identification of <i>Pbx1</i> , a Potential Oncogene, as a Notch3 Target Gene in Ovarian Cancer. <i>Cancer Research</i> , 2008, 68, 8852-8860.	0.4	66
211	The Roles of Human Sucrose Nonfermenting Protein 2 Homologue in the Tumor-Promoting Functions of Rsf-1. <i>Cancer Research</i> , 2008, 68, 4050-4057.	0.4	53
212	Jagged-1 and Notch3 Juxtacrine Loop Regulates Ovarian Tumor Growth and Adhesion. <i>Cancer Research</i> , 2008, 68, 5716-5723.	0.4	113
213	Pathogenesis of Ovarian Cancer. <i>International Journal of Gynecological Pathology</i> , 2008, PAP, 151-60.	0.9	385
214	HSD3B1 as a Novel Trophoblast-associated Marker That Assists in the Differential Diagnosis of Trophoblastic Tumors and Tumorlike Lesions. <i>American Journal of Surgical Pathology</i> , 2008, 32, 236-242.	2.1	57
215	MicroRNA Expression and Identification of Putative miRNA Targets in Ovarian Cancer. <i>PLoS ONE</i> , 2008, 3, e2436.	1.1	303
216	NAC-1 Controls Cell Growth and Survival by Repressing Transcription of Gadd45GIP1, a Candidate Tumor Suppressor. <i>Cancer Research</i> , 2007, 67, 8058-8064.	0.4	64

#	ARTICLE	IF	CITATIONS
217	Notch Signaling, β -Secretase Inhibitors, and Cancer Therapy: Figure 1.. Cancer Research, 2007, 67, 1879-1882.	0.4	394
218	Measurement of Cyclin E Genomic Copy Number and Strand Length in Cell-Free DNA Distinguish Malignant versus Benign Effusions. Clinical Cancer Research, 2007, 13, 5805-5809.	3.2	21
219	The Development of High-grade Serous Carcinoma From Atypical Proliferative (Borderline) Serous Tumors and Low-grade Micropapillary Serous Carcinoma. American Journal of Surgical Pathology, 2007, 31, 1007-1012.	2.1	139
220	Immunohistochemistry of Choriocarcinoma. American Journal of Surgical Pathology, 2007, 31, 1726-1732.	2.1	80
221	Trophogram, an immunohistochemistry-based algorithmic approach, in the differential diagnosis of trophoblastic tumors and tumorlike lesions. Annals of Diagnostic Pathology, 2007, 11, 228-234.	0.6	82
222	Expression and clinical role of the bric-a-brac tramtrack broad complex/poxvirus and zinc protein NAC-1 in ovarian carcinoma effusions. Human Pathology, 2007, 38, 1030-1036.	1.1	30
223	Application of Human Leukocyte Antigen G Expression in the Diagnosis of Human Cancer. Human Immunology, 2007, 68, 272-276.	1.2	28
224	Gestational trophoblastic neoplasia pathogenesis and potential therapeutic targets. Lancet Oncology, The, 2007, 8, 642-650.	5.1	183
225	Biomarker Identification by Knowledge-Driven Multi-Level ICA and Motif Analysis. , 2007, , .		5
226	Amplicon profiles in ovarian serous carcinomas. International Journal of Cancer, 2007, 120, 2613-2617.	2.3	124
227	Ovarian cancer specific kallikrein profile in effusions. Gynecologic Oncology, 2007, 105, 501-507.	0.6	45
228	Clinical and biological significance of HLA-G expression in ovarian cancer. Seminars in Cancer Biology, 2007, 17, 436-443.	4.3	46
229	MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells. Diagnostic Cytopathology, 2007, 35, 756-760.	0.5	43
230	Pathogenesis of Gestational Trophoblastic Lesions. , 2007, , 157-166.		3
231	Expression of Rsf-1, a chromatin-remodeling gene, in ovarian and breast carcinoma. Human Pathology, 2006, 37, 1169-1175.	1.1	38
232	Cyclin E and p16 Immunoreactivity in Epithelioid Trophoblastic Tumor An Aid in Differential Diagnosis. American Journal of Surgical Pathology, 2006, 30, 1105-1110.	2.1	86
233	Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 449, 31-39.	1.4	80
234	Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biology and Therapy, 2006, 5, 779-785.	1.5	165

#	ARTICLE	IF	CITATIONS
235	Diffuse Mesothelin Expression Correlates with Prolonged Patient Survival in Ovarian Serous Carcinoma. <i>Clinical Cancer Research</i> , 2006, 12, 827-831.	3.2	81
236	Ubiquitin-Proteasome System Stress Sensitizes Ovarian Cancer to Proteasome Inhibitor-Induced Apoptosis. <i>Cancer Research</i> , 2006, 66, 3754-3763.	0.4	123
237	Gene Expression Signatures Differentiate Ovarian/Peritoneal Serous Carcinoma from Diffuse Malignant Peritoneal Mesothelioma. <i>Clinical Cancer Research</i> , 2006, 12, 5944-5950.	3.2	100
238	A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 18739-18744.	3.3	121
239	Homozygous deletion of MKK4 in ovarian serous carcinoma. <i>Cancer Biology and Therapy</i> , 2006, 5, 630-634.	1.5	48
240	Notch3 Gene Amplification in Ovarian Cancer. <i>Cancer Research</i> , 2006, 66, 6312-6318.	0.4	257
241	Apply innovative technologies to explore cancer genome. <i>Current Opinion in Oncology</i> , 2005, 17, 33-38.	1.1	37
242	Patterns of p53 Mutations Separate Ovarian Serous Borderline Tumors and Low- and High-grade Carcinomas and Provide Support for a New Model of Ovarian Carcinogenesis. <i>American Journal of Surgical Pathology</i> , 2005, 29, 218-224.	2.1	388
243	HLA-G Upregulation in Pre-Malignant and Malignant Lesions of the Gastrointestinal Tract. <i>International Journal of Gastrointestinal Cancer</i> , 2005, 35, 015-024.	0.4	42
244	Identification and characterization of membralin, a novel tumor-associated gene, in ovarian carcinoma. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 2005, 1730, 96-102.	2.4	12
245	HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma. <i>Gynecologic Oncology</i> , 2005, 96, 42-47.	0.6	90
246	Inactivation of the Mitogen-Activated Protein Kinase Pathway as a Potential Target-Based Therapy in Ovarian Serous Tumors with KRAS or BRAF Mutations. <i>Cancer Research</i> , 2005, 65, 1994-2000.	0.4	114
247	Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 14004-14009.	3.3	135
248	Molecular Pathogenesis of Ovarian Borderline Tumors: New Insights and Old Challenges. <i>Clinical Cancer Research</i> , 2005, 11, 7273-7279.	3.2	131
249	Nuclear size distinguishes low- from high-grade ovarian serous carcinoma and predicts outcome. <i>Human Pathology</i> , 2005, 36, 1049-1054.	1.1	30
250	Activation of Mitogen-Activated Protein Kinase Is Required for Migration and Invasion of Placental Site Trophoblastic Tumor. <i>American Journal of Pathology</i> , 2005, 167, 879-885.	1.9	27
251	Apolipoprotein E is required for cell proliferation and survival in ovarian cancer. <i>Cancer Research</i> , 2005, 65, 331-7.	0.4	97
252	Mutations of BRAF and KRAS Precede the Development of Ovarian Serous Borderline Tumors. <i>Cancer Research</i> , 2004, 64, 6915-6918.	0.4	186

#	ARTICLE	IF	CITATIONS
253	Characterization of Active Mitogen-Activated Protein Kinase in Ovarian Serous Carcinomas. <i>Clinical Cancer Research</i> , 2004, 10, 6432-6436.	3.2	121
254	Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 3089-3094.	3.3	175
255	Molecular genetic analysis of ovarian serous cystadenomas. <i>Laboratory Investigation</i> , 2004, 84, 778-784.	1.7	53
256	Profiling the activity of G proteins in patient-derived tissues by rapid affinity-capture of signal transduction proteins (GRASP). <i>Proteomics</i> , 2004, 4, 812-818.	1.3	14
257	Principle and applications of digital PCR. <i>Expert Review of Molecular Diagnostics</i> , 2004, 4, 41-47.	1.5	189
258	Ovarian Tumorigenesis. <i>American Journal of Pathology</i> , 2004, 164, 1511-1518.	1.9	1,107
259	p63 Expression Is Useful in the Distinction of Epithelioid Trophoblastic and Placental Site Trophoblastic Tumors by Profiling Trophoblastic Subpopulations. <i>American Journal of Surgical Pathology</i> , 2004, 28, 1177-1183.	2.1	147
260	Mutations in BRAF and KRAS Characterize the Development of Low-Grade Ovarian Serous Carcinoma. <i>Journal of the National Cancer Institute</i> , 2003, 95, 484-486.	3.0	762
261	Mutational Analysis of K-ras Segregates Ovarian Serous Carcinomas into Two Types: Invasive MPSC (Low-grade Tumor) and Conventional Serous Carcinoma (High-grade Tumor). <i>International Journal of Gynecological Pathology</i> , 2003, 22, 37-41.	0.9	116
262	Increased plasma DNA integrity in cancer patients. <i>Cancer Research</i> , 2003, 63, 3966-8.	0.4	252
263	Identifying tumor origin using a gene expression-based classification map. <i>Cancer Research</i> , 2003, 63, 4144-9.	0.4	84
264	HLA-G is a potential tumor marker in malignant ascites. <i>Clinical Cancer Research</i> , 2003, 9, 4460-4.	3.2	141
265	The role of chromosomal instability in tumor initiation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 16226-16231.	3.3	484
266	Molecular Basis of Gestational Trophoblastic Diseases. <i>Current Molecular Medicine</i> , 2002, 2, 1-12.	0.6	73
267	Assessment of Plasma DNA Levels, Allelic Imbalance, and CA 125 as Diagnostic Tests for Cancer. <i>Journal of the National Cancer Institute</i> , 2002, 94, 1697-1703.	3.0	119
268	HLA-G Immunoreactivity Is Specific for Intermediate Trophoblast in Gestational Trophoblastic Disease and Can Serve as a Useful Marker in Differential Diagnosis. <i>American Journal of Surgical Pathology</i> , 2002, 26, 914-920.	2.1	125
269	Diverse Tumorigenic Pathways in Ovarian Serous Carcinoma. <i>American Journal of Pathology</i> , 2002, 160, 1223-1228.	1.9	320
270	Molecular Genetic Analysis of Placental Site Trophoblastic Tumors and Epithelioid Trophoblastic Tumors Confirms Their Trophoblastic Origin. <i>American Journal of Pathology</i> , 2002, 161, 1033-1037.	1.9	67

#	ARTICLE	IF	CITATIONS
271	APC/CTNNB1 (β -catenin) pathway alterations in human prostate cancers. <i>Genes Chromosomes and Cancer</i> , 2002, 34, 9-16.	1.5	152
272	The Role of E-cadherin in the Motility and Invasion of Implantation Site Intermediate Trophoblast. <i>Placenta</i> , 2002, 23, 706-15.	0.7	42
273	Proteomic Approaches to Tumor Marker Discovery. <i>Archives of Pathology and Laboratory Medicine</i> , 2002, 126, 1518-1526.	1.2	203
274	Molecular Genetic Analysis of Appendiceal Mucinous Adenomas in Identical Twins, Including One With Pseudomyxoma Peritonei. <i>American Journal of Surgical Pathology</i> , 2001, 25, 1095-1099.	2.1	38
275	The Pathology of Intermediate Trophoblastic Tumors and Tumor-like Lesions. <i>International Journal of Gynecological Pathology</i> , 2001, 20, 31-47.	0.9	277
276	Placental Site Trophoblastic Tumor—Past as Prologue. <i>Gynecologic Oncology</i> , 2001, 82, 413-414.	0.6	14
277	Assessing tumors in living animals through measurement of urinary β -human chorionic gonadotropin. <i>Nature Medicine</i> , 2000, 6, 711-714.	15.2	37
278	Placental site nodule and characterization of distinctive types of intermediate trophoblast. <i>Human Pathology</i> , 1999, 30, 687-694.	1.1	118
279	Ki-67 labeling index in the differential diagnosis of exaggerated placental site, placental site trophoblastic tumor, and choriocarcinoma: A double immunohistochemical staining technique using Ki-67 and Mel-CAM antibodies. <i>Human Pathology</i> , 1998, 29, 27-33.	1.1	143
280	Epithelioid Trophoblastic Tumor. <i>American Journal of Surgical Pathology</i> , 1998, 22, 1393-1403.	2.1	336